Ackermann JR, LeFor WM, Kahana L, Weinstein S, Shires DL. Prophylactic use of OKT3 in renal transplantation: part of a prospective randomised multicentre trial. Transplantation Proceedings 20 (Suppl 1): 242–244, 1988 Google Scholar
Acuto O, Reinherz EL. The human T-cell receptor: structure and function. New England Journal of Medicine 312: 1100–1111, 1985 ArticlePubMedCAS Google Scholar
Baudrihaye M-F, Chateroud L, Kreis H, Goldstein G, Bach J-F. Unusually restricted anti-isotype human immune response to OKT3 monoclonal antibody. European Journal of Immunology 14: 686–691, 1984 ArticlePubMedCAS Google Scholar
Biddison WE, Rao PE, Talle MA, Goldstein G, Shaw S. Possible involvement of the OKT4 molecule in T cell recognition of class II HLA antigens. Journal of Experimental Medicine 156: 1065–1076, 1982 ArticlePubMedCAS Google Scholar
Bowen A, Edwards LC, Gailiunas P, Helderman JH. Lymphocyte function in patients treated with monoclonal anti-T3 antibody for acute cadaveric renal allograft rejection. Transplantation 38: 489–493, 1984 ArticlePubMedCAS Google Scholar
Bristow MR, Gilbert EM, Renlund DG, De Witt CW, Burton NA, et al. Use of OKT3, monoclonal antibody in heart transplantation: review of the initial experience. Journal of Heart Transplantation 7: 1–11, 1988b Google Scholar
Bristow MR, Renlund DG, Gilbert EM, Lee HR, Gay WA, et al. Murine monoclonal CD3 antibody in cardiac transplantation: anti-rejection treatment and preliminary results in a prospectively randomised trial for prophylaxis. Clinical Transplantation 2: 163–168, 1988a Google Scholar
Canafax DM, Draxler CA. Monoclonal antilymphocyte antibody (OKT3) treatment of acute renal allograft rejection. Pharmacotherapy 7: 121–124, 1987 PubMedCAS Google Scholar
Carpenter CB, Milford EL, Reinherz EL, et al. Transactions of the Association of American Physicians 16: 84, 1983 Google Scholar
Ceuppens JL, Bloemmen FJ, Van Wauwe JP. T cell unresponsiveness to the mitogenic activity of OKT3 antibody results from a deficiency of monocyte Fc-alpha receptors for murine IgG2a and inability to cross-link the T3-Ti complex. Journal of Immunology 135: 3882, 1985 CAS Google Scholar
Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anaemia. New England Journal of Medicine 308: 113–118, 1983 ArticlePubMedCAS Google Scholar
Chang T-W, Gingras SP. OKT3 monoclonal inhibits cytotoxic T lymphocyte mediated cell lysis. International Journal of Immunopharmacology 3: 183–186, 1981 ArticlePubMedCAS Google Scholar
Chang T-W, Kung PC, Gingras SP, Goldstein G. Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells. Proceedings of the National Academy of Sciences (USA) 78: 1805–1808, 1981 ArticleCAS Google Scholar
Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Bach JF. Immunologic follow-up of renal allograft recipients treated prophylactically by OKT3 alone. Transplantation Proceedings 15: 643–645, 1983 Google Scholar
Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, et al. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. Journal of Immunology 137: 830–838, 1986 CAS Google Scholar
Chatenoud L, Baudrihaye MF, Kreis H, Goldstein G, Schindler J, et al. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. European Journal of Immunology 12: 979–982, 1982 ArticlePubMedCAS Google Scholar
Chatenoud L, Jonker M, Villemain F, Goldstein G, Bach, J-F. The human immune response to OKT3 monoclonal antibody is oligoclonal. Science 232: 1406–1408, 1986a ArticlePubMedCAS Google Scholar
Chou S, Norman DJ. Effect of OKT3 antibody therapy on cytomegaloviris reactivation in renal transplant recipients. Transplantation Proceedings 17: 2755–2756, 1985 Google Scholar
Colonna JO, Goldstein LI, Brems JJ, Vargas JH, Brill JE, et al. A prospective study on the use of monoclonal anti-T3-cell antibody (OKT3) to treat steroid-resistant liver transplant rejection. Archives of Surgery 122: 1120–1123, 1987 ArticlePubMed Google Scholar
Committee on Human Leukocyte Differentiation Antigens. Differentiation of human leukocyte antigens: a proposed nomenclature. Immunology Today 5: 158–159, 1984 Article Google Scholar
Cosimi AB. Diagnostic and therapeutic applications of monoclonal antibodies to human T-cell subsets in renal transplant recipients. Urologic Clinics of North America 10: 289–299, 1983 PubMedCAS Google Scholar
Cosimi AB. Clinical development of Orthoclone OKT3. Transplantation Proceedings 14 (Suppl. 1): 7–16, 1987 Google Scholar
Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, et al. Treatment of acute renal allograft rejection with 0KT3 monoclonal antibody. Transplantation 32: 535–539, 1981a ArticlePubMedCAS Google Scholar
Cosimi AB, Cho SI, Delmonico FL, Kaplan MM, Rohrer RJ, et al. A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplantation 43: 91–95, 1987 ArticlePubMedCAS Google Scholar
Cosimi AB, Colvin RB, Burton RC, Rubin RH, Goldstein G, et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. New England Journal of Medicine 305: 308–314, 1981b ArticlePubMedCAS Google Scholar
Costanzo-Nordin MR, Silver MA, O’Connell JB, Pifarre R, Grady KL, et al. Successful reversal of acute cardiac allograft rejection with OKT3 monoclonal antibody. Circulation 76 (Suppl. V): V71–V80, 1987 PubMedCAS Google Scholar
D’Alessandro AM, Pirsch JD, Stratta RJ, Sollinger HW, Kalayoglu M, et al. OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation. Transplantation 47: 297–300, 1989 ArticlePubMed Google Scholar
Debure A, Chkoff N, Chatenoud L, Lacombe M, Campos H, et al. Traitement prophylactique du rejet par l’administration prolongée d’OKT3: diminution de la re’ponse immune de l’hôte. Néphrologie 8: 87–94, 1987 PubMedCAS Google Scholar
Debure A, Chkoff N, Chatenoud L, Lacombe M, Campos H, et al. One month prophylactic use of OKT3 in cadaver kidney transplant recipients; Transplantation 45: 546–553, 1988 CAS Google Scholar
Deierhoi MH, Barber WH, Curtis JJ, Julian BA, Luke RG, et al. A comparison of OKT3 monoclonal antibody and corticosteroids in the treatment of acute renal allograft rejection. American Journal of Kidney Diseases 11: 86–89, 1988 PubMedCAS Google Scholar
Emmons C, Smith J, Flanigan M. Cerebrospinal fluid inflammation during OKT3 therapy. Correspondence. Lancet 2: 510–511, 1986 ArticlePubMedCAS Google Scholar
Ettenger RB, Marik J, Rosenthal JT, Malekzadeh MH, Salusky IB, et al. OKT3 for rejection reversal in pediatric renal transplantation. Clinical Transplantation 2: 180–184, 1988 Google Scholar
Filipovich AH, Krawczak CL, Kersey JH, McGlave P, Ramsay NKC, et al. Graft-versus-host disease prophylaxis with anti-T-cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone-marrow transplantation. British Journal of Haematology 60: 143–152, 1985 ArticlePubMedCAS Google Scholar
Filipovich AH, McGlave PB, Ramsay NKC, Goldstein G, Warkentin PI, et al. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation. Lancet 1: 1266–1269, 1982 ArticlePubMedCAS Google Scholar
First MR, Schroeder TJ, Hurtubise PE, Mansour ME, Penn I, et al. Successful retreatment of allograft rejection with OKT3. Transplantation 47: 88–91, 1989 ArticlePubMedCAS Google Scholar
First MR, Schroeder TJ, Melvin DB, Munda R, Fidler JP, et al. OKT3 therapy in kidney, liver, heart and pancreas transplantation. Clinical Transplantation 2: 185–189, 1988 Google Scholar
Ford HR, Fryd DS, Canafax FM, et al. Adjunctive azathioprine and antilymphocyte serum immunosuppression with cyclosporine. Transplant Proceedings 20 (Suppl. 3): 8–12, 1988 CAS Google Scholar
Fung JJ, Markus BH, Gordon RD, Esquivel CO, Makowka L, et al. Impact of Orthoclone OKT3 on liver transplantation. Transplantation Proceedings 19 (Suppl. 1): 37–44, 1987 PubMedCAS Google Scholar
Gilbert EM, DeWitt CW, Eiswirth CC, Renlund DG, Menlove RL, et al. Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. American Journal of Medicine 82: 202–206, 1987b ArticlePubMedCAS Google Scholar
Gilbert EM, Eiswirth CC, Renlund DG, Menlove RL, DeWitt CW, et al. Use of Orthoclone OKT3 monoclonal antibody in cardiac transplantation: early experience with rejection prophylaxis and treatment of refractory rejection. Transplantation Proceedings 19 (Suppl. 1): 45–53, 1987a PubMedCAS Google Scholar
Gilbert EM, Renlund DG, O’Connell JB, Biswirth CC, Rothstein G, et al. Immunosuppressive efficacy of vincristine in heart transplantation: a preliminary report. Journal of Heart Transplantation 6: 369–374, 1987c PubMedCAS Google Scholar
Gilmore MJML, Prentice HG, Price Jones E, Blacklock HA, Tidman N, et al. Allogeneic bone marrow transplantation: the monitoring of granulocyte macrophage colonies following the collection of bone marrow mononuclear cells and after the subsequent in vitro cytolysis of OKT3 positive lymphocytes. British Journal of Haematology 55: 587–593, 1983 ArticlePubMedCAS Google Scholar
Giorgi JV, Cosimi AB, Colvin RB, Goldstein G, Delmonico FL, et al. Monitoring immunosuppression following renal transplantation. Diagnostic Immunology 1: 174–178, 1983 PubMedCAS Google Scholar
Gluckman E, Devergie A, Varin F, Rabian C, D’Agay MF, et al. Treatment of steroid resistant severe acute graft versus host disease with a monoclonal PANT OKT3 antibody. Experimental Haematology 2 (Suppl. 15): 66–67, 1984 Google Scholar
Goldstein G. Overview of the development of Orthoclone OKT3 monoclonal antibody for therapeutic use in transplantation. Transplantation Proceedings 19 (Suppl.): 1–6, 1987 PubMedCAS Google Scholar
Goldstein G, Fuccello AJ, Norman DJ, Shield CF, Colvin RB, et al. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation 42: 507–510, 1986a ArticlePubMedCAS Google Scholar
Goldstein G, Norman DJ, Shield CF, Kreis H, Burdick J. OKT3 monoclonal antibody reversal of acute renal allograft rejection unresponsive to conventional immunosuppressive treatments. In Meryman HT (Ed.) Transplantation: approaches to graft rejection, pp. 239–249, Alan R. Liss Inc, New York, 1986b Google Scholar
Gordon RD, Starzl TE, Fung JJ, Iwatsuki S, Esquivel CO, et al. Monoclonal antibody therapy with ciclosporin and steroids in nonmatched cadaveric renal transplants. Nephron 46 (Suppl. 1): 56–59, 1987 ArticlePubMed Google Scholar
Gordon RD, Tzakis AG, Iwatsuki S, Todo S, Esquivel CO, et al. Experience with orthoclone OKT3 monoclonal antibody in liver transplantation. American Journal of Kidney Diseases 11: 141–144, 1988 PubMedCAS Google Scholar
Gratama JW, Jansen J, Lipovich RA, Tanke HJ, Goldstein G, et al. Treatment of acute graft-versus-host disease with monoclonal antibody OKT3. Transplantation 38: 469–474, 1984 ArticlePubMedCAS Google Scholar
Hall BM, Tiller DJ, Hardie I, et al. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long term cyclosporine, short term cyclosporine followed by azathioprine and prednisolone and azathioprine and prednisolone without cyclosporine. New England Journal of Medicine 318: 1499–1507, 1988 ArticlePubMedCAS Google Scholar
Herrick CM, Mealey PC, Hagan ME, Holland CS, Volkman AK, et al. Rejection prophylaxis with murine monoclonal CD3 antibody (OKT3): considerations for early hospital discharge. Journal of Heart Transplantation 8: 67–70, 1989 PubMedCAS Google Scholar
Herve P, Flesch M, Cahn JY, Racadot E, Plouvier E, et al. Removal of marrow T cells with OKT3-OKT11 monoclonal antibodies and complement to prevent acute graft-versus-host disease. Transplantation 39: 138–143, 1985 ArticlePubMedCAS Google Scholar
Hirsch RL, Goldstein G. Orthoclone OKT3 in the treatment of acute renal allograft rejection. Dialysis and Transplantation 15: 659–662, 1986 Google Scholar
Hirsch RL, Layton PC, Barnes LA, Kremer AB, Goldstein G. Orthoclone OKT3 treatment of acute renal allograft rejection in patients receiving maintenance cyclosporine therapy. Transplantation Proceedings 19 (Suppl. 1): 32–36, 1987 PubMedCAS Google Scholar
Hosenpud JD, Norman DJ, Pantely GA, Cobanoglu MA, Starr A. Low morbidity and mortality from infection following cardiac transplantation using maintenance triple therapy and low dose corticosteroids for acute rejection. Clinical Transplantation 2: 201–206, 1988 Google Scholar
Hricik DE, Zarconi J, Schulak JA. Influence of low-dose cyclosporine on the outcome of treatment with OKT3 for acute renal allograft rejection. Transplantation 47: 272–277, 1989 ArticlePubMedCAS Google Scholar
Jaffers GJ, Colvin RB, Cosimi AB, Giorgi JV, Goldstein G, et al. The human immune response to murine OKT3 monoclonal antibody. Transplantation Proceedings 15: 646–648, 1983 Google Scholar
Jansen J, Gratama JW, Zwann FE, Simonis RFA. Therapy with monoclonal antibody OKT3 in severe aplastic anaemia. Experimental Haematology 12 (Suppl. 15): 46–47, 1984 Google Scholar
Jansen J, Veenhof WFJ, Goselink HM. Anti-thymocyte globulin effective in the treatment of aplastic anemia does not stimulate granulocyte precursor cells. Experimental Hematology 9: 1028–1034, 1981 PubMedCAS Google Scholar
Jansen J, Zwann FE, Simonis RFA, et al. Therapy in severe aplastic anemia: bone marrow transplantation or antilymphocyte globulin? Experimental Haematology 10 (Supp. 12): 132–138, 1982 Google Scholar
Kahana L, Baxter JA, OKT3 rescue in refractory renal rejection. Nephron 46 (Suppl. 1): 34–40, 1987 ArticlePubMed Google Scholar
Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497, 1975 ArticlePubMed Google Scholar
Kreis H, Chkoff N, Chatenoud L, Campos H, Bach JF, et al. Prolonged administration of a monoclonal anti-T3 cell antibody (Orthoclone OKT3) to kidney allograft recipients. Transplantation Proceedings 18: 954–956, 1986 Google Scholar
Kremer AB, Barnes L, Hirsch RL, Goldstein G. Orthoclone OKT3 monoclonal antibody reversal of hepatic and cardiac allograft rejection unresponsive to conventional immunosuppressive treatments. Transplantation Proceedings 19 (Suppl. 1): 54–57, 1987 PubMedCAS Google Scholar
Kung PC, Goldstein G, Reinherz EL, Schlossman SF. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 206: 347–349, 1979 ArticlePubMedCAS Google Scholar
Landegren U, Ramstedt V, Axberg I, Ullberg M, Jondal M, et al. Selective inhibition of human T cell cytotoxicity at levels of target recognition or initiation of lysis by monoclonal OKT3 and Leu-2a antibodies. Journal of Experimental Medicine 155: 1579–1584, 1982 ArticlePubMedCAS Google Scholar
Lau C, Goldstein G. OKT3 induces suppressor cells for mixed lymphocyte and PHA mitogenic responses in human peripheral lymphocytes. International Journal of Immunopharmacology 3: 187–192, 1981 ArticlePubMedCAS Google Scholar
Leone MR, Alexander SR, Barry JM, Henell K, Funneil MB, et al. OKT3 monoclonal antibody in pediatric kidney transplant recipients with recurrent and resistant allograft rejection. Journal of Pediatrics 111: 45–50, 1987 ArticlePubMedCAS Google Scholar
Markus BH, Fung JJ, Gordon RD, Iwatsuki S, Esquivel CO, et al. Effect of OKT3 on survival and rate of retransplantation. Transplantation Proceedings 19 (Suppl. 3): 61–62, 1987 PubMedCAS Google Scholar
Martin MA, Massanari RM, Nghiem DD, Smith JL, Corry RJ. Nosocomial aseptic meningitis associated with administration of OKT3. Journal of the American Medical Association 259: 2002–2005, 1988 ArticlePubMedCAS Google Scholar
Mayes JT, Thistlethwaite JR, Stuart JK, Buckingham MR, Stuart FP. Reexposure to OKT3 in renal allograft recipients. Transplantation 45: 349–353, 1988 ArticlePubMedCAS Google Scholar
Meuer SC, Hussey RE, Hogdon JC, Hercend T, Schlossman SF, et al. Surface structures involved in target recognition by human cytotoxic T lymphocytes. Science 218: 471–473, 1982 ArticlePubMedCAS Google Scholar
Miller RA, Maloney DG, McKillop J, Levy R. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 58: 78–86, 1981 PubMedCAS Google Scholar
Millis JM, McDiarmid SV, Hiatt JR, Brems JJ, Colonna JO, et al. Randomised prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation. Transplantation 47: 82–88, 1989 ArticlePubMedCAS Google Scholar
Nelson PW, Jaffers GJ, Fuller TC, Cosimi AB, Colvin RB. Reduction of immune response to OKT3 monoclonal antibody. Transplantation Proceedings 17: 644–645, 1985 Google Scholar
Norman DJ, Barry JM, Bennett WM, Leone M, Henell K, et al. The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy. American Journal of Kidney Diseases 11: 90–93, 1988a PubMedCAS Google Scholar
Norman DJ, Shield CF, Barry J, Bennett WM, Henell K, et al. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection. American Journal of Renal Diseases 11: 107–110, 1988b CAS Google Scholar
Norman DJ, Shield CF, Barry J, Henell K, Funnell B, et al. A US clinical study of Orthoclone OKT3 in renal transplantation. Transplantation Proceedings 19 (Suppl. 1): 21–27, 1987 PubMedCAS Google Scholar
Norman DJ, Shield CF, Henell KR, Kimball J, Barry JM, et al. Effectiveness of a second course of OKT3 monoclonal anti-T-cell antibody for treatment of renal allograft rejection. Transplantation 46: 523–529, 1988c ArticlePubMedCAS Google Scholar
Oh C-S, Stratta RJ, Fox BC, Sollinger HW, Beizen FO, et al. Increased infections associated with the use of OKT3 for treatment of steroid resistant rejection in renal transplantation. Transplantation 45: 68–73, 1988 ArticlePubMedCAS Google Scholar
Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. New England Journal of Medicine 313: 337–342, 1985 Article Google Scholar
Palacios R. Cyclosporin-A and the OKT*3 monoclonal antibody exert their respective inhibitory and mitogenic activity on T cells by interacting with the same receptors. Journal of Clinical Immunology 2 (Suppl.): 15S–19S, 1982 ArticlePubMedCAS Google Scholar
Ponticelli C, Rivolta E, Tarantino A, DeVecchi A, Vegeto A. Rescue of severe steroid-resistant rejection with OKT3. PAN. Transplantation Proceedings 19: 1908–1909, 1987 PubMedCAS Google Scholar
Poplawski S, Gonwa TA, Greene C, Husberg BS, Klintmalm G. Interstitial nephritis secondary to OKT3 administration. Clinical Transplantation 2: 341–343, 1988 Google Scholar
Prentice HG, Blacklock HA, Janossy G, Bradstock KF, Skeggs D, et al. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Lancet 1: 700–703, 1982 ArticlePubMedCAS Google Scholar
Reinherz EL, Hussey RE, Fitzgerald KA, Snow P, Terhorst C, et al. Antibody directed at a surface structure inhibits cytolytic but not suppressor function of human T lymphocytes. Nature 299: 168–170, 1981 Article Google Scholar
Reinherz EL, Hussey RE, Schlossman SF. A monoclonal antibody blocking human T cell function. European Journal of Immunology 10: 758–762, 1980 ArticlePubMedCAS Google Scholar
Reinherz EL, Meuer S, Fitzgerald KA, Hussey RE, Levine H, et al. Antigen recognition by human T lymphocytes is linked to surface expression of the T3 molecular complex. Cell 30: 735–743, 1982 ArticlePubMedCAS Google Scholar
Robinson CP. Muromonab-CD3 (Orthoclone OKT3®): a review. Drugs of Today 22: 603–609, 1986 CAS Google Scholar
Rohrer RJ, Jenkins RL, Khettry U, Benotti PN, Dodson TF, et al. Histological response to OKT3 therapy for hepatic allograft rejection. Transplantation Proceedings 19: 2459–2461, 1987 PubMedCAS Google Scholar
Rowe PA, Rocker GM, Morgan AG, Shale DJ. OKT3 and pulmonary capillary permeability. British Medical Journal 295: 1099–1100, 1987 ArticlePubMedCAS Google Scholar
Russell PS, Colvin RB, Cosimi AB. Monoclonal antibodies for the diagnosis and treatment of transplant rejection. Annual Reviews of Medicine 35: 63–79, 1984 ArticleCAS Google Scholar
Shield CF, Norman DJ, Marlett P, Fucello AJ, Goldstein G. Comparison of antimouse and antihorse antibody production during the treatment of allograft rejection with OKT3 or antithymocyte globulin. Nephron 46 (Suppl. 1): 48–51, 1987 ArticlePubMed Google Scholar
Shield CF, Cosimi AB, Rubin RM, Tolkoff-Rubin NE, Herrin J, et al. Use of antithymocyte globulin for reversal of acute allograft rejection. Transplantation 28: 461–464, 1979 PubMed Google Scholar
Shield CF, Hughes JD, Lemon JA. Prophylactic OKT3 and cadaveric renal transplantation at a single center. Clinical Transplantation 2: 190–193, 1988 Google Scholar
Singh N, Dummer JS, Kusne S, Breinig MK, Armstrong JA, et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. Journal of Infectious Diseases 158: 124–131, 1988 ArticlePubMedCAS Google Scholar
Sinnott JT, Cullison JP, Sweeney MS, Weinstein SS. Infections in patients receiving OKT3 monoclonal antibody for cardiac rejection. Texas Heart Institute Journal 15: 102–106, 1988 PubMed Google Scholar
Skamene E, Russell PS. A quantitative study of the binding of ALS to various cell types. Clinical and Experimental Immunology 8: 195, 1971 PubMedCAS Google Scholar
Speck B, Gratwohl A, Nissen C, et al. Treatment of severe aplastic anaemia with antilymphocyte globulin or bone-marrow transplantation. British Medical Journal 282: 860–863, 1981 ArticlePubMedCAS Google Scholar
Starzl TE, Fung JJ. Orthoclone OKT3 in treatment of allografts rejected under cyclosporine-steroid therapy. Transplantation Proceedings 18: 937–941, 1986 PubMed Google Scholar
Stratta RJ, D’Alessandro AM, Hoffmann RM, Sollinger HW, Kalayoglu M, et al. Cadaveric renal transplantation in the cyclosporine and OKT3 eras. Surgery 104: 606–615, 1988 PubMedCAS Google Scholar
Takahashi H, Okazaki H, Terasaki PI, Iwaki Y, Kinukawa T, et al. Reversal of transplant rejection by monoclonal antiblast antibody. Lancet 2: 1155–1157, 1983 ArticlePubMedCAS Google Scholar
Thistlethwaite JR, Stuart JK, Mayes JT, Gaber AO, Woodle S, et al. Complications and monitoring of OKT3 therapy. American Journal of Kidney Diseases 11: 112–119, 1988c PubMed Google Scholar
Thistlethwaite Jr JR, Cosimi AB, DelMonico FL, Rubin RH, Tal-koff-Rubin N, et al. Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection. Transplantation 38: 695–701, 1984 ArticlePubMed Google Scholar
Thistlethwaite Jr JR, Haag BW, Gaber AO, Stuart JK, Aronson AJ, et al. The use of OKT3 to treat steroid-resistant renal allograft rejection in patients receiving cyclosporine. Transplantation Proceedings 19: 1901–1904, 1987 PubMed Google Scholar
Thistlethwaite JR, Stuart JK, Mayes JT, Graber O, Stuart FP. Use of a brief steroid trial before initiating OKT3 therapy for renal allograft rejection. American Journal of Kidney Diseases 11: 94–98, 1988a PubMed Google Scholar
Thomas DM, Nicholls AJ, Feest TG, Riad H. OKT3 and cerebral oedema. British Medical Journal 295: 1486, 1987 ArticlePubMedCAS Google Scholar
Thomas F, Thomas J, Flora R, Mendez-Picon G, Peace K, et al. Effect of antilymphocyte-globulin potency on survival of cadaver renal transplants. Lancet 2: 671, 1977 ArticlePubMedCAS Google Scholar
Thurlow PJ, Lovering E, d’Apice AJF, McKenzie IF. A monoclonal anti-pan-T-cell antibody: in vitro and in vivo studies. Transplantation 36: 293–298, 1983 ArticlePubMedCAS Google Scholar
Van Wauwe JP, DeMey JR, Goosens JG. OKT3: a monoclonal anti-human T-cell antibody with potent mitogenic properties. Journal of Immunology 124: 2708–2713, 1980 Google Scholar
Von Wussow P, Platsoucos CD, Wiranowsha-Stewart M, Stewart WE. Human γ interferon production by leukocytes induced with monoclonal antibodies recognizing T cells. Journal of Immunology 27: 1197–1200, 1981 Google Scholar
Waymack JP, Penn I, First MR, Alexander JW. Portal vein gas and sepsis after administration of OKT3. Lancet 1: 984, 1987 ArticlePubMedCAS Google Scholar
Wechter WJ, Brodie JA, Morrel RM, Rafi M, Schulz JR. Anti-thymocyte globulin (ATGAM) in renal allograft recipients. Transplantation 28: 294, 1979 ArticlePubMedCAS Google Scholar
Weimar W, Essed CE, Balk AHMM, Simoons ML, Hendriks CFJ, et al. OKT3 delays rejection crises after heart transplantation. Transplantation Proceedings 21: 2497–2498, 1989 PubMedCAS Google Scholar
Widmer U, Frei D, Keusch G, Burger HR, Largiader F, et al. OKT3 treatment of steroid-and/or anti-thymocyte globulin-resistant renal allograft rejection occurring on triple baseline immunosuppression including cyclosporine A. Transplantation Proceedings 20 (Suppl. 6): 90–95, 1988 PubMedCAS Google Scholar
Winde G, Dietl KH, Raidt H, Buchholz B, Lison AE, et al. Use of orthoclone OKT3 as treatment of acute renal allograft rejection and as first-line therapy in kidney transplantation. Transplantation Proceedings 20 (Suppl 6): 87–89, 1988 PubMedCAS Google Scholar
Zepp F, Mannhardt W, Düber J, Gehler J, Beetz R, et al. Successful bone marrow transplantation (BMT) in two patients with severe combined immunodeficiency (SCID) using SBA-lectin and OKT-3 pretreated non-identical (unrelated) bone marrow (BM). Experimental Hematology 12 (Suppl. 15): 89–90, 1984 Google Scholar